28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
The interventions were positively perceived, with 72.0% finding the consultation informative and 69.2% considering the app useful. 5 key findings →
Design: randomized controlled trial Participants: 188 Evidence: high
Full summary, score breakdown and related studies → Original source
Prevention of cognitive impairment and dementia is an important public health goal. 4 key findings →
Design: systematic review Participants: 11,140 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Profiles of high risk for future dementia are well understood and are likely to concern mostly those in low-income and middle-income countries and people at greater disadvantage in high-income countries. 1 key finding →
Design: randomized controlled trial Participants: 2,400 Evidence: high
Full summary, score breakdown and related studies → Original source
We investigated the effects of renin-angiotensin system blockade on cognitive function in patients aged 55 years and older with established atherosclerotic cardiovascular disease or diabetes with end-organ damage in two clinical trials. 4 key findings →
Design: randomized controlled trial Participants: 620 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Compared with UC, CCT increased scores on the MDRS's total, attention, and memory and those on the Mini-Mental State Examination and Telephone Interview of Cognitive Status over the 6-month intervention; TC increased scores on the MDRS's total and conceptualization and those on the Mini-Mental State Examination over the 6-month intervention, while it also increased scores on the MDRS's total and initiation/preservation and those on the Telephone Interview of Cognitive Status and reduced the time to complete the Trail Making Test B over the 12-month study. 3 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source
Some observational studies raised concern that statins may cause memory impairment, leading to a US Food and Drug Administration warning. 1 key finding →
Evidence: high
Full summary, score breakdown and related studies → Original source
IR is related to subsequent poorer cognitive performance and greater cognitive decline among patients with cardiovascular disease with and without diabetes. 3 key findings →
Participants: 558 Evidence: low
Full summary, score breakdown and related studies → Original source
This study is based on a population-based cohort of 7,839 subjects over 65 years with 7 years of follow-up. 4 key findings →
Design: longitudinal study Participants: 7,839 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Cardiovascular risk factors and a history of vascular disease can increase the risk of Alzheimer's disease (AD). 4 key findings →
Design: randomized controlled trial Participants: 156 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Contrary to early case-control studies that suggested smoking protects against Alzheimer disease (AD), recent prospective studies have shown that elderly who smoke may be at increased risk for dementia. 4 key findings →
Design: case-control study Participants: 17,610 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Depression, socioeconomic status, hearing handicap, loneliness, education, smoking, tinnitus, little exercise, small social network, stroke, diabetes, and hypertension were all associated with impairments in at least one cognitive measure. 5 key findings →
Design: cross-sectional Participants: 3,327 Evidence: low
Full summary, score breakdown and related studies → Original source
We examined whether cognitive function at baseline affected cognitive and cardiovascular outcomes in the Study on COgnition and Prognosis in the Elderly (SCOPE), a blood pressure (BP)-lowering intervention trial. 4 key findings →
Design: open-label trial Participants: 2,070 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
We thus examined whether higher blood cholesterol concentrations were associated with faster cognitive decline in a community-based longitudinal study of Chinese elderly. 4 key findings →
Design: longitudinal study Participants: 90 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The aim of this observational study was to evaluate whether the treatment of VRF is associated with a slower cognitive decline in patients who have AD without cerebrovascular disease (CVD). 4 key findings →
Participants: 72 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
In univariate analysis, all 29 adiposity and metabolic measures assessed were associated with ' g ' at P < 0.05. 5 key findings →
Participants: 8,769 Evidence: moderate
Full summary, score breakdown and related studies → Original source
The role of atrial fibrillation in cognitive impairment and dementia, independent of stroke, is uncertain. 4 key findings →
Design: post-hoc analysis Participants: 31,506 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Although cross-sectional studies found an association between anaemia and dementia, longitudinal studies provided contradictory results. 4 key findings →
Design: cross-sectional Participants: 1,139 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
A decreasing linear trend was observed between higher levels of curry consumption and cognitive decline (p = 0.037). 4 key findings →
Design: cohort study Participants: 2,920 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Higher concentrations of pTau181 and GFAP were associated with slower responses on working memory tasks (pTau181: β = 0.261; p = 0.007; GFAP: β = 0.175, p = 0.036), and higher β-amyloid 42/40 ratio was associated with better vocabulary (β = 0.260, p = 0.009). 4 key findings →
Participants: 114 Evidence: low
Full summary, score breakdown and related studies → Original source
The independent and combined effects of physical and cognitive domains of frailty in predicting the development of mild cognitive impairment (MCI) or dementia are not firmly established. 2 key findings →
Design: cross-sectional Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Caregivers play a major role in the care of patients with dementia and are themselves at higher risk of disease. 4 key findings →
Participants: 548 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Significant hazard ratios (HRs) for dementia incidence were found using the MMSE cutoff between 23 and 24 point (HR 1.93, 95% CI 1.13-3.27) and the J-Cog cutoff between 43 and 44 points (HR 2.42, 95% CI 1.50-3.93). 4 key findings →
Design: case-control study Participants: 100 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
In 893 participants with average age 93 years (range 90-102), 43 % had SMC. 5 key findings →
Design: cross-sectional Participants: 893 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Extended monitoring detects subclinical epileptiform activity in a substantial proportion of patients with AD. 2 key findings →
Participants: 33 Evidence: low
Full summary, score breakdown and related studies → Original source
This pilot study is the first trial evaluating the potential benefits of home-based tailored and adaptive CCT in relation to cognitive and disease self-management in older diabetic adults. 4 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →